nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—JAK3—hematologic cancer	0.0507	0.148	CbGaD
Crizotinib—TXK—hematologic cancer	0.0384	0.112	CbGaD
Crizotinib—FLT3—hematologic cancer	0.0384	0.112	CbGaD
Crizotinib—ABL2—hematologic cancer	0.0342	0.1	CbGaD
Crizotinib—LCK—hematologic cancer	0.0327	0.0954	CbGaD
Crizotinib—FGR—hematologic cancer	0.0291	0.0851	CbGaD
Crizotinib—MET—hematologic cancer	0.0242	0.0708	CbGaD
Crizotinib—JAK2—hematologic cancer	0.0221	0.0645	CbGaD
Crizotinib—ALK—hematologic cancer	0.0207	0.0606	CbGaD
Crizotinib—CSF1R—hematologic cancer	0.0197	0.0575	CbGaD
Crizotinib—ABL1—hematologic cancer	0.0153	0.0447	CbGaD
Crizotinib—SRC—hematologic cancer	0.0138	0.0404	CbGaD
Crizotinib—ANKK1—Ruxolitinib—hematologic cancer	0.0127	0.031	CbGbCtD
Crizotinib—DCLK1—Ruxolitinib—hematologic cancer	0.0127	0.031	CbGbCtD
Crizotinib—TESK1—Dasatinib—hematologic cancer	0.0108	0.0264	CbGbCtD
Crizotinib—TAOK2—Ruxolitinib—hematologic cancer	0.00918	0.0224	CbGbCtD
Crizotinib—TYK2—Ruxolitinib—hematologic cancer	0.00918	0.0224	CbGbCtD
Crizotinib—JAK3—Ruxolitinib—hematologic cancer	0.00918	0.0224	CbGbCtD
Crizotinib—TIE1—Nilotinib—hematologic cancer	0.00886	0.0216	CbGbCtD
Crizotinib—TXK—Dasatinib—hematologic cancer	0.00783	0.0191	CbGbCtD
Crizotinib—SIK2—Dasatinib—hematologic cancer	0.00783	0.0191	CbGbCtD
Crizotinib—LIMK2—Dasatinib—hematologic cancer	0.00783	0.0191	CbGbCtD
Crizotinib—RIPK2—Dasatinib—hematologic cancer	0.00783	0.0191	CbGbCtD
Crizotinib—LTK—Ruxolitinib—hematologic cancer	0.00729	0.0178	CbGbCtD
Crizotinib—JAK2—Ruxolitinib—hematologic cancer	0.00729	0.0178	CbGbCtD
Crizotinib—NUAK2—Ruxolitinib—hematologic cancer	0.00729	0.0178	CbGbCtD
Crizotinib—BMP2K—Ruxolitinib—hematologic cancer	0.00729	0.0178	CbGbCtD
Crizotinib—MAP4K1—Nilotinib—hematologic cancer	0.00704	0.0172	CbGbCtD
Crizotinib—EPHA4—Nilotinib—hematologic cancer	0.00704	0.0172	CbGbCtD
Crizotinib—EPHA3—Nilotinib—hematologic cancer	0.00704	0.0172	CbGbCtD
Crizotinib—EPHB4—Nilotinib—hematologic cancer	0.00704	0.0172	CbGbCtD
Crizotinib—NTRK1—Imatinib—hematologic cancer	0.00648	0.0158	CbGbCtD
Crizotinib—AURKA—Epirubicin—hematologic cancer	0.00626	0.0153	CbGbCtD
Crizotinib—EPHA3—Dasatinib—hematologic cancer	0.00622	0.0152	CbGbCtD
Crizotinib—EPHA4—Dasatinib—hematologic cancer	0.00622	0.0152	CbGbCtD
Crizotinib—BMPR1B—Dasatinib—hematologic cancer	0.00622	0.0152	CbGbCtD
Crizotinib—EPHA5—Dasatinib—hematologic cancer	0.00622	0.0152	CbGbCtD
Crizotinib—JAK2—Dasatinib—hematologic cancer	0.00622	0.0152	CbGbCtD
Crizotinib—EPHB4—Dasatinib—hematologic cancer	0.00622	0.0152	CbGbCtD
Crizotinib—TNK2—Dasatinib—hematologic cancer	0.00622	0.0152	CbGbCtD
Crizotinib—STK35—Dasatinib—hematologic cancer	0.00622	0.0152	CbGbCtD
Crizotinib—PLK4—Ruxolitinib—hematologic cancer	0.0061	0.0149	CbGbCtD
Crizotinib—TAOK3—Ruxolitinib—hematologic cancer	0.0061	0.0149	CbGbCtD
Crizotinib—MAP3K3—Ruxolitinib—hematologic cancer	0.0061	0.0149	CbGbCtD
Crizotinib—TEK—Nilotinib—hematologic cancer	0.00589	0.0144	CbGbCtD
Crizotinib—EPHA2—Nilotinib—hematologic cancer	0.00589	0.0144	CbGbCtD
Crizotinib—EPHA8—Nilotinib—hematologic cancer	0.00589	0.0144	CbGbCtD
Crizotinib—IRAK1—Ruxolitinib—hematologic cancer	0.00527	0.0129	CbGbCtD
Crizotinib—MAP3K2—Ruxolitinib—hematologic cancer	0.00527	0.0129	CbGbCtD
Crizotinib—MAP4K5—Dasatinib—hematologic cancer	0.0052	0.0127	CbGbCtD
Crizotinib—YES1—Dasatinib—hematologic cancer	0.0052	0.0127	CbGbCtD
Crizotinib—MAP3K3—Dasatinib—hematologic cancer	0.0052	0.0127	CbGbCtD
Crizotinib—EPHA8—Dasatinib—hematologic cancer	0.0052	0.0127	CbGbCtD
Crizotinib—EPHA2—Dasatinib—hematologic cancer	0.0052	0.0127	CbGbCtD
Crizotinib—FGR—Nilotinib—hematologic cancer	0.00509	0.0124	CbGbCtD
Crizotinib—LYN—Nilotinib—hematologic cancer	0.0045	0.011	CbGbCtD
Crizotinib—BLK—Nilotinib—hematologic cancer	0.0045	0.011	CbGbCtD
Crizotinib—EPHA6—Nilotinib—hematologic cancer	0.0045	0.011	CbGbCtD
Crizotinib—EPHB6—Nilotinib—hematologic cancer	0.0045	0.011	CbGbCtD
Crizotinib—MAP3K2—Dasatinib—hematologic cancer	0.0045	0.011	CbGbCtD
Crizotinib—FGR—Dasatinib—hematologic cancer	0.0045	0.011	CbGbCtD
Crizotinib—CSF1R—Imatinib—hematologic cancer	0.00445	0.0109	CbGbCtD
Crizotinib—ABL2—Imatinib—hematologic cancer	0.00445	0.0109	CbGbCtD
Crizotinib—LCK—Imatinib—hematologic cancer	0.00405	0.00988	CbGbCtD
Crizotinib—ABL2—Nilotinib—hematologic cancer	0.00404	0.00986	CbGbCtD
Crizotinib—CSF1R—Nilotinib—hematologic cancer	0.00404	0.00986	CbGbCtD
Crizotinib—LYN—Dasatinib—hematologic cancer	0.00398	0.0097	CbGbCtD
Crizotinib—BLK—Dasatinib—hematologic cancer	0.00398	0.0097	CbGbCtD
Crizotinib—SRC—Dasatinib—hematologic cancer	0.00398	0.0097	CbGbCtD
Crizotinib—EPHB6—Dasatinib—hematologic cancer	0.00398	0.0097	CbGbCtD
Crizotinib—LCK—Nilotinib—hematologic cancer	0.00368	0.00898	CbGbCtD
Crizotinib—ABL2—Dasatinib—hematologic cancer	0.00357	0.00872	CbGbCtD
Crizotinib—CSF1R—Dasatinib—hematologic cancer	0.00357	0.00872	CbGbCtD
Crizotinib—MAP3K19—Ruxolitinib—hematologic cancer	0.0035	0.00855	CbGbCtD
Crizotinib—AURKA—Doxorubicin—hematologic cancer	0.00333	0.00812	CbGbCtD
Crizotinib—LCK—Dasatinib—hematologic cancer	0.00325	0.00793	CbGbCtD
Crizotinib—ABL1—Imatinib—hematologic cancer	0.00322	0.00785	CbGbCtD
Crizotinib—MAP3K19—Dasatinib—hematologic cancer	0.00299	0.00729	CbGbCtD
Crizotinib—ABL1—Nilotinib—hematologic cancer	0.00292	0.00713	CbGbCtD
Crizotinib—ABCB1—hematologic cancer	0.00283	0.00826	CbGaD
Crizotinib—ABL1—Dasatinib—hematologic cancer	0.00258	0.0063	CbGbCtD
Crizotinib—ABCB1—Lenalidomide—hematologic cancer	0.00059	0.00144	CbGbCtD
Crizotinib—CYP3A5—Daunorubicin—hematologic cancer	0.000531	0.0013	CbGbCtD
Crizotinib—CYP3A5—Thalidomide—hematologic cancer	0.000484	0.00118	CbGbCtD
Crizotinib—CYP3A5—Teniposide—hematologic cancer	0.000462	0.00113	CbGbCtD
Crizotinib—CYP3A5—Ifosfamide—hematologic cancer	0.000426	0.00104	CbGbCtD
Crizotinib—CYP3A5—Imatinib—hematologic cancer	0.000407	0.000993	CbGbCtD
Crizotinib—CYP3A4—Bexarotene—hematologic cancer	0.000353	0.000862	CbGbCtD
Crizotinib—ABCB1—Daunorubicin—hematologic cancer	0.000346	0.000844	CbGbCtD
Crizotinib—ABCB1—Alitretinoin—hematologic cancer	0.000339	0.000827	CbGbCtD
Crizotinib—CYP3A4—Busulfan—hematologic cancer	0.000329	0.000802	CbGbCtD
Crizotinib—CYP3A4—Lomustine—hematologic cancer	0.000329	0.000802	CbGbCtD
Crizotinib—CYP3A5—Dasatinib—hematologic cancer	0.000327	0.000798	CbGbCtD
Crizotinib—CYP3A4—Thiotepa—hematologic cancer	0.000293	0.000714	CbGbCtD
Crizotinib—ABCB1—Imatinib—hematologic cancer	0.000265	0.000646	CbGbCtD
Crizotinib—CYP3A5—Irinotecan—hematologic cancer	0.000254	0.00062	CbGbCtD
Crizotinib—ABCB1—Nilotinib—hematologic cancer	0.000241	0.000587	CbGbCtD
Crizotinib—ABCB1—Vinorelbine—hematologic cancer	0.000239	0.000582	CbGbCtD
Crizotinib—CYP3A4—Methoxsalen—hematologic cancer	0.000228	0.000556	CbGbCtD
Crizotinib—CYP3A5—Vincristine—hematologic cancer	0.000222	0.000542	CbGbCtD
Crizotinib—CYP3A4—Bortezomib—hematologic cancer	0.000217	0.000528	CbGbCtD
Crizotinib—ABCB1—Dasatinib—hematologic cancer	0.000213	0.000519	CbGbCtD
Crizotinib—ABCB1—Mitoxantrone—hematologic cancer	0.00021	0.000513	CbGbCtD
Crizotinib—CYP3A4—Daunorubicin—hematologic cancer	0.000207	0.000505	CbGbCtD
Crizotinib—CYP3A5—Etoposide—hematologic cancer	0.000204	0.000497	CbGbCtD
Crizotinib—ABCB1—Betamethasone—hematologic cancer	0.000187	0.000457	CbGbCtD
Crizotinib—ABCB1—Gemcitabine—hematologic cancer	0.000186	0.000453	CbGbCtD
Crizotinib—ABCB1—Prednisolone—hematologic cancer	0.000185	0.000451	CbGbCtD
Crizotinib—CYP3A4—Cytarabine—hematologic cancer	0.000183	0.000446	CbGbCtD
Crizotinib—CYP3A4—Teniposide—hematologic cancer	0.00018	0.000439	CbGbCtD
Crizotinib—ABCB1—Prednisone—hematologic cancer	0.000175	0.000426	CbGbCtD
Crizotinib—CYP3A5—Dexamethasone—hematologic cancer	0.000167	0.000408	CbGbCtD
Crizotinib—CYP3A4—Ifosfamide—hematologic cancer	0.000166	0.000405	CbGbCtD
Crizotinib—ABCB1—Irinotecan—hematologic cancer	0.000165	0.000404	CbGbCtD
Crizotinib—CYP3A4—Imatinib—hematologic cancer	0.000159	0.000387	CbGbCtD
Crizotinib—CYP3A4—Ruxolitinib—hematologic cancer	0.000149	0.000365	CbGbCtD
Crizotinib—ABCB1—Vinblastine—hematologic cancer	0.000147	0.000359	CbGbCtD
Crizotinib—ALK—lung—hematologic cancer	0.000147	0.00266	CbGeAlD
Crizotinib—FER—lung—hematologic cancer	0.000147	0.00266	CbGeAlD
Crizotinib—STK4—testis—hematologic cancer	0.000147	0.00266	CbGeAlD
Crizotinib—LIMK1—lymph node—hematologic cancer	0.000146	0.00264	CbGeAlD
Crizotinib—TNK1—lung—hematologic cancer	0.000145	0.00264	CbGeAlD
Crizotinib—YES1—hematopoietic system—hematologic cancer	0.000145	0.00263	CbGeAlD
Crizotinib—ABCB1—Vincristine—hematologic cancer	0.000145	0.000353	CbGbCtD
Crizotinib—CYP3A4—Nilotinib—hematologic cancer	0.000144	0.000352	CbGbCtD
Crizotinib—LIMK2—blood—hematologic cancer	0.000144	0.00261	CbGeAlD
Crizotinib—BMPR1B—lung—hematologic cancer	0.000144	0.00261	CbGeAlD
Crizotinib—MAP4K1—lung—hematologic cancer	0.000144	0.00261	CbGeAlD
Crizotinib—MAP3K19—lung—hematologic cancer	0.000144	0.00261	CbGeAlD
Crizotinib—STK10—hematopoietic system—hematologic cancer	0.000144	0.00261	CbGeAlD
Crizotinib—NUAK2—blood—hematologic cancer	0.000144	0.0026	CbGeAlD
Crizotinib—TAOK3—hematopoietic system—hematologic cancer	0.000143	0.0026	CbGeAlD
Crizotinib—CYP3A4—Vinorelbine—hematologic cancer	0.000143	0.000349	CbGbCtD
Crizotinib—EPHA4—gonad—hematologic cancer	0.000143	0.00259	CbGeAlD
Crizotinib—MAP3K12—blood—hematologic cancer	0.000143	0.00258	CbGeAlD
Crizotinib—FLT3—blood—hematologic cancer	0.000143	0.00258	CbGeAlD
Crizotinib—ACVR1—blood—hematologic cancer	0.000143	0.00258	CbGeAlD
Crizotinib—MERTK—bone marrow—hematologic cancer	0.000143	0.00258	CbGeAlD
Crizotinib—PRKD3—lymph node—hematologic cancer	0.000142	0.00258	CbGeAlD
Crizotinib—TNK2—lung—hematologic cancer	0.000141	0.00256	CbGeAlD
Crizotinib—IGF1R—lung—hematologic cancer	0.000141	0.00256	CbGeAlD
Crizotinib—MAP3K2—gonad—hematologic cancer	0.00014	0.00254	CbGeAlD
Crizotinib—SRC—hematopoietic system—hematologic cancer	0.00014	0.00253	CbGeAlD
Crizotinib—MAP4K2—lung—hematologic cancer	0.000139	0.00252	CbGeAlD
Crizotinib—NUAK2—bone marrow—hematologic cancer	0.000139	0.00252	CbGeAlD
Crizotinib—TYRO3—testis—hematologic cancer	0.000139	0.00251	CbGeAlD
Crizotinib—FER—testis—hematologic cancer	0.000139	0.00251	CbGeAlD
Crizotinib—ALK—testis—hematologic cancer	0.000139	0.00251	CbGeAlD
Crizotinib—DSTYK—lymph node—hematologic cancer	0.000139	0.00251	CbGeAlD
Crizotinib—FLT3—bone marrow—hematologic cancer	0.000138	0.0025	CbGeAlD
Crizotinib—ACVR1—bone marrow—hematologic cancer	0.000138	0.0025	CbGeAlD
Crizotinib—STK3—lung—hematologic cancer	0.000137	0.00249	CbGeAlD
Crizotinib—TIE1—lung—hematologic cancer	0.000137	0.00249	CbGeAlD
Crizotinib—TNK1—testis—hematologic cancer	0.000137	0.00249	CbGeAlD
Crizotinib—PTK2—gonad—hematologic cancer	0.000137	0.00249	CbGeAlD
Crizotinib—TBK1—gonad—hematologic cancer	0.000137	0.00249	CbGeAlD
Crizotinib—BLK—lymph node—hematologic cancer	0.000137	0.00249	CbGeAlD
Crizotinib—ABL2—blood—hematologic cancer	0.000136	0.00247	CbGeAlD
Crizotinib—MAP4K1—testis—hematologic cancer	0.000136	0.00246	CbGeAlD
Crizotinib—BMPR1B—testis—hematologic cancer	0.000136	0.00246	CbGeAlD
Crizotinib—MAP3K19—testis—hematologic cancer	0.000136	0.00246	CbGeAlD
Crizotinib—LTK—lymph node—hematologic cancer	0.000136	0.00246	CbGeAlD
Crizotinib—CASK—lymph node—hematologic cancer	0.000136	0.00246	CbGeAlD
Crizotinib—ABCB1—Cisplatin—hematologic cancer	0.000135	0.000329	CbGbCtD
Crizotinib—BMP2K—blood—hematologic cancer	0.000134	0.00244	CbGeAlD
Crizotinib—AURKA—lung—hematologic cancer	0.000134	0.00243	CbGeAlD
Crizotinib—TNK2—testis—hematologic cancer	0.000133	0.00242	CbGeAlD
Crizotinib—IGF1R—testis—hematologic cancer	0.000133	0.00242	CbGeAlD
Crizotinib—TESK1—lung—hematologic cancer	0.000133	0.00241	CbGeAlD
Crizotinib—ABCB1—Etoposide—hematologic cancer	0.000133	0.000323	CbGbCtD
Crizotinib—MAP4K2—testis—hematologic cancer	0.000131	0.00238	CbGeAlD
Crizotinib—MAPK7—lymph node—hematologic cancer	0.000131	0.00238	CbGeAlD
Crizotinib—TXK—lymph node—hematologic cancer	0.000131	0.00238	CbGeAlD
Crizotinib—CYP3A4—Triamcinolone—hematologic cancer	0.000131	0.000319	CbGbCtD
Crizotinib—AXL—gonad—hematologic cancer	0.000131	0.00237	CbGeAlD
Crizotinib—BMP2K—bone marrow—hematologic cancer	0.00013	0.00236	CbGeAlD
Crizotinib—FES—lymph node—hematologic cancer	0.00013	0.00236	CbGeAlD
Crizotinib—PTK2B—blood—hematologic cancer	0.00013	0.00235	CbGeAlD
Crizotinib—STK3—testis—hematologic cancer	0.00013	0.00235	CbGeAlD
Crizotinib—TIE1—testis—hematologic cancer	0.00013	0.00235	CbGeAlD
Crizotinib—MERTK—lung—hematologic cancer	0.000129	0.00234	CbGeAlD
Crizotinib—RIPK2—blood—hematologic cancer	0.000129	0.00233	CbGeAlD
Crizotinib—CYP3A4—Dasatinib—hematologic cancer	0.000127	0.000311	CbGbCtD
Crizotinib—LIMK2—lung—hematologic cancer	0.000126	0.00229	CbGeAlD
Crizotinib—AURKA—testis—hematologic cancer	0.000126	0.00229	CbGeAlD
Crizotinib—CYP3A4—Mitoxantrone—hematologic cancer	0.000126	0.000307	CbGbCtD
Crizotinib—NUAK2—lung—hematologic cancer	0.000126	0.00228	CbGeAlD
Crizotinib—PTK2B—bone marrow—hematologic cancer	0.000126	0.00228	CbGeAlD
Crizotinib—CSF1R—hematopoietic system—hematologic cancer	0.000125	0.00227	CbGeAlD
Crizotinib—TESK1—testis—hematologic cancer	0.000125	0.00227	CbGeAlD
Crizotinib—ACVR1—lung—hematologic cancer	0.000125	0.00227	CbGeAlD
Crizotinib—FLT3—lung—hematologic cancer	0.000125	0.00227	CbGeAlD
Crizotinib—MAP3K12—lung—hematologic cancer	0.000125	0.00227	CbGeAlD
Crizotinib—RIPK2—bone marrow—hematologic cancer	0.000125	0.00226	CbGeAlD
Crizotinib—EPHA4—blood—hematologic cancer	0.000124	0.00226	CbGeAlD
Crizotinib—JAK2—gonad—hematologic cancer	0.000124	0.00225	CbGeAlD
Crizotinib—MET—lymph node—hematologic cancer	0.000123	0.00223	CbGeAlD
Crizotinib—STK35—lung—hematologic cancer	0.000122	0.00222	CbGeAlD
Crizotinib—MAP3K2—blood—hematologic cancer	0.000122	0.00221	CbGeAlD
Crizotinib—MERTK—testis—hematologic cancer	0.000122	0.00221	CbGeAlD
Crizotinib—PTK2—blood—hematologic cancer	0.00012	0.00217	CbGeAlD
Crizotinib—TBK1—blood—hematologic cancer	0.00012	0.00217	CbGeAlD
Crizotinib—MAP3K3—gonad—hematologic cancer	0.000119	0.00217	CbGeAlD
Crizotinib—MAP4K5—gonad—hematologic cancer	0.000119	0.00217	CbGeAlD
Crizotinib—ABL2—lung—hematologic cancer	0.000119	0.00216	CbGeAlD
Crizotinib—LIMK2—testis—hematologic cancer	0.000119	0.00216	CbGeAlD
Crizotinib—CDK7—lymph node—hematologic cancer	0.000119	0.00215	CbGeAlD
Crizotinib—NUAK2—testis—hematologic cancer	0.000119	0.00215	CbGeAlD
Crizotinib—TYK2—blood—hematologic cancer	0.000119	0.00215	CbGeAlD
Crizotinib—MAP3K2—bone marrow—hematologic cancer	0.000118	0.00214	CbGeAlD
Crizotinib—MAP3K12—testis—hematologic cancer	0.000118	0.00214	CbGeAlD
Crizotinib—FLT3—testis—hematologic cancer	0.000118	0.00214	CbGeAlD
Crizotinib—ACVR1—testis—hematologic cancer	0.000118	0.00214	CbGeAlD
Crizotinib—TAOK2—lymph node—hematologic cancer	0.000118	0.00214	CbGeAlD
Crizotinib—BMP2K—lung—hematologic cancer	0.000118	0.00214	CbGeAlD
Crizotinib—IRAK1—blood—hematologic cancer	0.000117	0.00213	CbGeAlD
Crizotinib—TBK1—bone marrow—hematologic cancer	0.000116	0.0021	CbGeAlD
Crizotinib—STK35—testis—hematologic cancer	0.000115	0.00209	CbGeAlD
Crizotinib—RPS6KB1—blood—hematologic cancer	0.000115	0.00209	CbGeAlD
Crizotinib—TYK2—bone marrow—hematologic cancer	0.000115	0.00208	CbGeAlD
Crizotinib—FGR—blood—hematologic cancer	0.000114	0.00207	CbGeAlD
Crizotinib—LCK—blood—hematologic cancer	0.000114	0.00207	CbGeAlD
Crizotinib—PTK2B—lung—hematologic cancer	0.000114	0.00206	CbGeAlD
Crizotinib—EPHA3—lymph node—hematologic cancer	0.000114	0.00206	CbGeAlD
Crizotinib—ACVR1B—lymph node—hematologic cancer	0.000114	0.00206	CbGeAlD
Crizotinib—IRAK1—bone marrow—hematologic cancer	0.000113	0.00206	CbGeAlD
Crizotinib—RIPK2—lung—hematologic cancer	0.000113	0.00205	CbGeAlD
Crizotinib—ABL2—testis—hematologic cancer	0.000113	0.00204	CbGeAlD
Crizotinib—CYP3A4—Betamethasone—hematologic cancer	0.000112	0.000274	CbGbCtD
Crizotinib—RPS6KB1—bone marrow—hematologic cancer	0.000111	0.00202	CbGeAlD
Crizotinib—BMP2K—testis—hematologic cancer	0.000111	0.00202	CbGeAlD
Crizotinib—CYP3A4—Prednisolone—hematologic cancer	0.000111	0.00027	CbGbCtD
Crizotinib—LCK—bone marrow—hematologic cancer	0.000111	0.00201	CbGeAlD
Crizotinib—FGR—bone marrow—hematologic cancer	0.000111	0.00201	CbGeAlD
Crizotinib—YES1—gonad—hematologic cancer	0.00011	0.002	CbGeAlD
Crizotinib—SLK—blood—hematologic cancer	0.00011	0.00199	CbGeAlD
Crizotinib—STK10—gonad—hematologic cancer	0.000109	0.00198	CbGeAlD
Crizotinib—EPHA4—lung—hematologic cancer	0.000109	0.00198	CbGeAlD
Crizotinib—ABCB1—Dexamethasone—hematologic cancer	0.000109	0.000266	CbGbCtD
Crizotinib—EPHB4—blood—hematologic cancer	0.000109	0.00197	CbGeAlD
Crizotinib—JAK3—lymph node—hematologic cancer	0.000108	0.00196	CbGeAlD
Crizotinib—JAK2—blood—hematologic cancer	0.000108	0.00196	CbGeAlD
Crizotinib—DCLK1—lymph node—hematologic cancer	0.000108	0.00195	CbGeAlD
Crizotinib—PTK2B—testis—hematologic cancer	0.000107	0.00195	CbGeAlD
Crizotinib—MAP3K2—lung—hematologic cancer	0.000107	0.00194	CbGeAlD
Crizotinib—PLK4—lymph node—hematologic cancer	0.000107	0.00194	CbGeAlD
Crizotinib—EPHA2—blood—hematologic cancer	0.000107	0.00194	CbGeAlD
Crizotinib—RIPK2—testis—hematologic cancer	0.000106	0.00193	CbGeAlD
Crizotinib—STK4—lymph node—hematologic cancer	0.000106	0.00193	CbGeAlD
Crizotinib—SRC—gonad—hematologic cancer	0.000106	0.00193	CbGeAlD
Crizotinib—SLK—bone marrow—hematologic cancer	0.000106	0.00192	CbGeAlD
Crizotinib—EPHB4—bone marrow—hematologic cancer	0.000105	0.00191	CbGeAlD
Crizotinib—TBK1—lung—hematologic cancer	0.000105	0.0019	CbGeAlD
Crizotinib—PTK2—lung—hematologic cancer	0.000105	0.0019	CbGeAlD
Crizotinib—CYP3A4—Prednisone—hematologic cancer	0.000105	0.000255	CbGbCtD
Crizotinib—JAK2—bone marrow—hematologic cancer	0.000105	0.0019	CbGeAlD
Crizotinib—MAP3K3—blood—hematologic cancer	0.000104	0.00189	CbGeAlD
Crizotinib—MAP4K5—blood—hematologic cancer	0.000104	0.00189	CbGeAlD
Crizotinib—TEK—blood—hematologic cancer	0.000104	0.00189	CbGeAlD
Crizotinib—TYK2—lung—hematologic cancer	0.000104	0.00189	CbGeAlD
Crizotinib—EPHA4—testis—hematologic cancer	0.000103	0.00187	CbGeAlD
Crizotinib—IRAK1—lung—hematologic cancer	0.000103	0.00186	CbGeAlD
Crizotinib—MAP3K2—testis—hematologic cancer	0.000101	0.00183	CbGeAlD
Crizotinib—RPS6KB1—lung—hematologic cancer	0.000101	0.00183	CbGeAlD
Crizotinib—MAP4K5—bone marrow—hematologic cancer	0.000101	0.00183	CbGeAlD
Crizotinib—MAP3K3—bone marrow—hematologic cancer	0.000101	0.00183	CbGeAlD
Crizotinib—ALK—lymph node—hematologic cancer	0.000101	0.00182	CbGeAlD
Crizotinib—FER—lymph node—hematologic cancer	0.000101	0.00182	CbGeAlD
Crizotinib—LCK—lung—hematologic cancer	0.0001	0.00182	CbGeAlD
Crizotinib—FGR—lung—hematologic cancer	0.0001	0.00182	CbGeAlD
Crizotinib—AXL—lung—hematologic cancer	9.98e-05	0.00181	CbGeAlD
Crizotinib—EPHB6—blood—hematologic cancer	9.95e-05	0.0018	CbGeAlD
Crizotinib—TNK1—lymph node—hematologic cancer	9.95e-05	0.0018	CbGeAlD
Crizotinib—CYP3A4—Irinotecan—hematologic cancer	9.91e-05	0.000242	CbGbCtD
Crizotinib—ABL1—hematopoietic system—hematologic cancer	9.91e-05	0.0018	CbGeAlD
Crizotinib—TBK1—testis—hematologic cancer	9.89e-05	0.00179	CbGeAlD
Crizotinib—PTK2—testis—hematologic cancer	9.89e-05	0.00179	CbGeAlD
Crizotinib—MAP4K1—lymph node—hematologic cancer	9.85e-05	0.00179	CbGeAlD
Crizotinib—BMPR1B—lymph node—hematologic cancer	9.85e-05	0.00179	CbGeAlD
Crizotinib—TYK2—testis—hematologic cancer	9.82e-05	0.00178	CbGeAlD
Crizotinib—IRAK1—testis—hematologic cancer	9.69e-05	0.00176	CbGeAlD
Crizotinib—IGF1R—lymph node—hematologic cancer	9.66e-05	0.00175	CbGeAlD
Crizotinib—TNK2—lymph node—hematologic cancer	9.66e-05	0.00175	CbGeAlD
Crizotinib—YES1—blood—hematologic cancer	9.61e-05	0.00174	CbGeAlD
Crizotinib—SLK—lung—hematologic cancer	9.61e-05	0.00174	CbGeAlD
Crizotinib—EPHB4—lung—hematologic cancer	9.54e-05	0.00173	CbGeAlD
Crizotinib—CSF1R—gonad—hematologic cancer	9.53e-05	0.00173	CbGeAlD
Crizotinib—STK10—blood—hematologic cancer	9.53e-05	0.00173	CbGeAlD
Crizotinib—MAP4K2—lymph node—hematologic cancer	9.52e-05	0.00173	CbGeAlD
Crizotinib—RPS6KB1—testis—hematologic cancer	9.51e-05	0.00172	CbGeAlD
Crizotinib—TAOK3—blood—hematologic cancer	9.49e-05	0.00172	CbGeAlD
Crizotinib—JAK2—lung—hematologic cancer	9.47e-05	0.00172	CbGeAlD
Crizotinib—FGR—testis—hematologic cancer	9.45e-05	0.00171	CbGeAlD
Crizotinib—LCK—testis—hematologic cancer	9.45e-05	0.00171	CbGeAlD
Crizotinib—AXL—testis—hematologic cancer	9.42e-05	0.00171	CbGeAlD
Crizotinib—TIE1—lymph node—hematologic cancer	9.39e-05	0.0017	CbGeAlD
Crizotinib—STK3—lymph node—hematologic cancer	9.39e-05	0.0017	CbGeAlD
Crizotinib—EPHA2—lung—hematologic cancer	9.36e-05	0.0017	CbGeAlD
Crizotinib—YES1—bone marrow—hematologic cancer	9.3e-05	0.00169	CbGeAlD
Crizotinib—SRC—blood—hematologic cancer	9.25e-05	0.00168	CbGeAlD
Crizotinib—STK10—bone marrow—hematologic cancer	9.22e-05	0.00167	CbGeAlD
Crizotinib—TAOK3—bone marrow—hematologic cancer	9.18e-05	0.00167	CbGeAlD
Crizotinib—AURKA—lymph node—hematologic cancer	9.15e-05	0.00166	CbGeAlD
Crizotinib—MAP3K3—lung—hematologic cancer	9.13e-05	0.00166	CbGeAlD
Crizotinib—MAP4K5—lung—hematologic cancer	9.13e-05	0.00166	CbGeAlD
Crizotinib—TEK—lung—hematologic cancer	9.13e-05	0.00166	CbGeAlD
Crizotinib—TESK1—lymph node—hematologic cancer	9.08e-05	0.00165	CbGeAlD
Crizotinib—SLK—testis—hematologic cancer	9.06e-05	0.00164	CbGeAlD
Crizotinib—ABCB1—Doxorubicin—hematologic cancer	9.04e-05	0.000221	CbGbCtD
Crizotinib—EPHB4—testis—hematologic cancer	9e-05	0.00163	CbGeAlD
Crizotinib—JAK2—testis—hematologic cancer	8.93e-05	0.00162	CbGeAlD
Crizotinib—IGF1R—Topotecan—Irinotecan—hematologic cancer	8.86e-05	0.0474	CbGdCrCtD
Crizotinib—MERTK—lymph node—hematologic cancer	8.83e-05	0.0016	CbGeAlD
Crizotinib—EPHA2—testis—hematologic cancer	8.83e-05	0.0016	CbGeAlD
Crizotinib—CYP3A4—Vinblastine—hematologic cancer	8.81e-05	0.000215	CbGbCtD
Crizotinib—ABCB1—Methotrexate—hematologic cancer	8.76e-05	0.000214	CbGbCtD
Crizotinib—EPHB6—lung—hematologic cancer	8.72e-05	0.00158	CbGeAlD
Crizotinib—CYP3A4—Vincristine—hematologic cancer	8.67e-05	0.000211	CbGbCtD
Crizotinib—LIMK2—lymph node—hematologic cancer	8.64e-05	0.00157	CbGeAlD
Crizotinib—MAP4K5—testis—hematologic cancer	8.61e-05	0.00156	CbGeAlD
Crizotinib—MAP3K3—testis—hematologic cancer	8.61e-05	0.00156	CbGeAlD
Crizotinib—TEK—testis—hematologic cancer	8.61e-05	0.00156	CbGeAlD
Crizotinib—NUAK2—lymph node—hematologic cancer	8.61e-05	0.00156	CbGeAlD
Crizotinib—ACVR1—lymph node—hematologic cancer	8.55e-05	0.00155	CbGeAlD
Crizotinib—FLT3—lymph node—hematologic cancer	8.55e-05	0.00155	CbGeAlD
Crizotinib—MAP3K12—lymph node—hematologic cancer	8.55e-05	0.00155	CbGeAlD
Crizotinib—YES1—lung—hematologic cancer	8.43e-05	0.00153	CbGeAlD
Crizotinib—STK35—lymph node—hematologic cancer	8.37e-05	0.00152	CbGeAlD
Crizotinib—STK10—lung—hematologic cancer	8.35e-05	0.00151	CbGeAlD
Crizotinib—TAOK3—lung—hematologic cancer	8.32e-05	0.00151	CbGeAlD
Crizotinib—CSF1R—blood—hematologic cancer	8.3e-05	0.00151	CbGeAlD
Crizotinib—EPHB6—testis—hematologic cancer	8.23e-05	0.00149	CbGeAlD
Crizotinib—ABL2—lymph node—hematologic cancer	8.16e-05	0.00148	CbGeAlD
Crizotinib—SRC—lung—hematologic cancer	8.11e-05	0.00147	CbGeAlD
Crizotinib—BMP2K—lymph node—hematologic cancer	8.06e-05	0.00146	CbGeAlD
Crizotinib—CSF1R—bone marrow—hematologic cancer	8.03e-05	0.00146	CbGeAlD
Crizotinib—YES1—testis—hematologic cancer	7.95e-05	0.00144	CbGeAlD
Crizotinib—CYP3A4—Etoposide—hematologic cancer	7.94e-05	0.000194	CbGbCtD
Crizotinib—STK10—testis—hematologic cancer	7.88e-05	0.00143	CbGeAlD
Crizotinib—TAOK3—testis—hematologic cancer	7.85e-05	0.00142	CbGeAlD
Crizotinib—PTK2B—lymph node—hematologic cancer	7.78e-05	0.00141	CbGeAlD
Crizotinib—RIPK2—lymph node—hematologic cancer	7.72e-05	0.0014	CbGeAlD
Crizotinib—SRC—testis—hematologic cancer	7.65e-05	0.00139	CbGeAlD
Crizotinib—ABL1—gonad—hematologic cancer	7.53e-05	0.00137	CbGeAlD
Crizotinib—EPHA4—lymph node—hematologic cancer	7.46e-05	0.00135	CbGeAlD
Crizotinib—MAP3K2—lymph node—hematologic cancer	7.32e-05	0.00133	CbGeAlD
Crizotinib—CSF1R—lung—hematologic cancer	7.28e-05	0.00132	CbGeAlD
Crizotinib—TBK1—lymph node—hematologic cancer	7.17e-05	0.0013	CbGeAlD
Crizotinib—PTK2—lymph node—hematologic cancer	7.17e-05	0.0013	CbGeAlD
Crizotinib—CDK7—Topotecan—Irinotecan—hematologic cancer	7.14e-05	0.0382	CbGdCrCtD
Crizotinib—TYK2—lymph node—hematologic cancer	7.12e-05	0.00129	CbGeAlD
Crizotinib—IRAK1—lymph node—hematologic cancer	7.03e-05	0.00127	CbGeAlD
Crizotinib—RPS6KB1—lymph node—hematologic cancer	6.89e-05	0.00125	CbGeAlD
Crizotinib—CSF1R—testis—hematologic cancer	6.87e-05	0.00125	CbGeAlD
Crizotinib—FGR—lymph node—hematologic cancer	6.85e-05	0.00124	CbGeAlD
Crizotinib—LCK—lymph node—hematologic cancer	6.85e-05	0.00124	CbGeAlD
Crizotinib—AXL—lymph node—hematologic cancer	6.82e-05	0.00124	CbGeAlD
Crizotinib—SLK—lymph node—hematologic cancer	6.57e-05	0.00119	CbGeAlD
Crizotinib—ABL1—blood—hematologic cancer	6.56e-05	0.00119	CbGeAlD
Crizotinib—CYP3A4—Dexamethasone—hematologic cancer	6.53e-05	0.000159	CbGbCtD
Crizotinib—EPHB4—lymph node—hematologic cancer	6.52e-05	0.00118	CbGeAlD
Crizotinib—JAK2—lymph node—hematologic cancer	6.48e-05	0.00117	CbGeAlD
Crizotinib—EPHA2—lymph node—hematologic cancer	6.4e-05	0.00116	CbGeAlD
Crizotinib—ABL1—bone marrow—hematologic cancer	6.35e-05	0.00115	CbGeAlD
Crizotinib—AURKA—Chlorambucil—Melphalan—hematologic cancer	6.31e-05	0.0338	CbGdCrCtD
Crizotinib—TEK—lymph node—hematologic cancer	6.24e-05	0.00113	CbGeAlD
Crizotinib—MAP3K3—lymph node—hematologic cancer	6.24e-05	0.00113	CbGeAlD
Crizotinib—MAP4K5—lymph node—hematologic cancer	6.24e-05	0.00113	CbGeAlD
Crizotinib—IGF1R—Idarubicin—Daunorubicin—hematologic cancer	5.98e-05	0.032	CbGdCrCtD
Crizotinib—EPHB6—lymph node—hematologic cancer	5.97e-05	0.00108	CbGeAlD
Crizotinib—CYP3A5—hematopoietic system—hematologic cancer	5.8e-05	0.00105	CbGeAlD
Crizotinib—YES1—lymph node—hematologic cancer	5.76e-05	0.00105	CbGeAlD
Crizotinib—ABL1—lung—hematologic cancer	5.75e-05	0.00104	CbGeAlD
Crizotinib—STK10—lymph node—hematologic cancer	5.71e-05	0.00104	CbGeAlD
Crizotinib—TAOK3—lymph node—hematologic cancer	5.69e-05	0.00103	CbGeAlD
Crizotinib—SRC—lymph node—hematologic cancer	5.55e-05	0.00101	CbGeAlD
Crizotinib—ABL1—testis—hematologic cancer	5.43e-05	0.000985	CbGeAlD
Crizotinib—CYP3A4—Doxorubicin—hematologic cancer	5.42e-05	0.000132	CbGbCtD
Crizotinib—CSF1R—lymph node—hematologic cancer	4.98e-05	0.000903	CbGeAlD
Crizotinib—CDK7—Idarubicin—Daunorubicin—hematologic cancer	4.82e-05	0.0258	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Daunorubicin—hematologic cancer	4.82e-05	0.0258	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Daunorubicin—hematologic cancer	4.82e-05	0.0258	CbGdCrCtD
Crizotinib—PLK4—Topotecan—Irinotecan—hematologic cancer	4.65e-05	0.0249	CbGdCrCtD
Crizotinib—PLK4—Etoposide—Teniposide—hematologic cancer	4.62e-05	0.0247	CbGdCrCtD
Crizotinib—CYP3A4—hematopoietic system—hematologic cancer	4.35e-05	0.000789	CbGeAlD
Crizotinib—CASK—Teniposide—Etoposide—hematologic cancer	4.25e-05	0.0227	CbGdCrCtD
Crizotinib—ABL1—lymph node—hematologic cancer	3.94e-05	0.000714	CbGeAlD
Crizotinib—ABL1—Topotecan—Irinotecan—hematologic cancer	3.91e-05	0.0209	CbGdCrCtD
Crizotinib—CYP3A5—blood—hematologic cancer	3.84e-05	0.000697	CbGeAlD
Crizotinib—CDK7—Daunorubicin—Idarubicin—hematologic cancer	3.65e-05	0.0196	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Idarubicin—hematologic cancer	3.65e-05	0.0196	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Idarubicin—hematologic cancer	3.65e-05	0.0196	CbGdCrCtD
Crizotinib—AURKA—Topotecan—Irinotecan—hematologic cancer	3.64e-05	0.0195	CbGdCrCtD
Crizotinib—AURKA—Etoposide—Teniposide—hematologic cancer	3.62e-05	0.0194	CbGdCrCtD
Crizotinib—CYP3A5—lung—hematologic cancer	3.37e-05	0.000611	CbGeAlD
Crizotinib—PLK4—Idarubicin—Daunorubicin—hematologic cancer	3.14e-05	0.0168	CbGdCrCtD
Crizotinib—PLK4—Doxorubicin—Daunorubicin—hematologic cancer	3.14e-05	0.0168	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Daunorubicin—hematologic cancer	3.14e-05	0.0168	CbGdCrCtD
Crizotinib—ABCB1—hematopoietic system—hematologic cancer	3.08e-05	0.000559	CbGeAlD
Crizotinib—CYP3A4—blood—hematologic cancer	2.88e-05	0.000523	CbGeAlD
Crizotinib—PLK4—Menadione—Thalidomide—hematologic cancer	2.67e-05	0.0143	CbGdCrCtD
Crizotinib—ABL1—Doxorubicin—Daunorubicin—hematologic cancer	2.64e-05	0.0141	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Daunorubicin—hematologic cancer	2.64e-05	0.0141	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Daunorubicin—hematologic cancer	2.64e-05	0.0141	CbGdCrCtD
Crizotinib—AURKA—Floxuridine—Pentostatin—hematologic cancer	2.51e-05	0.0134	CbGdCrCtD
Crizotinib—AURKA—Doxorubicin—Daunorubicin—hematologic cancer	2.46e-05	0.0132	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Daunorubicin—hematologic cancer	2.46e-05	0.0132	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Daunorubicin—hematologic cancer	2.46e-05	0.0132	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Idarubicin—hematologic cancer	2.38e-05	0.0127	CbGdCrCtD
Crizotinib—PLK4—Doxorubicin—Idarubicin—hematologic cancer	2.38e-05	0.0127	CbGdCrCtD
Crizotinib—ABCB1—gonad—hematologic cancer	2.34e-05	0.000425	CbGeAlD
Crizotinib—PLK4—Teniposide—Etoposide—hematologic cancer	2.1e-05	0.0112	CbGdCrCtD
Crizotinib—AURKA—Menadione—Thalidomide—hematologic cancer	2.09e-05	0.0112	CbGdCrCtD
Crizotinib—IGF1R—Idarubicin—Epirubicin—hematologic cancer	2.08e-05	0.0111	CbGdCrCtD
Crizotinib—ABCB1—blood—hematologic cancer	2.04e-05	0.00037	CbGeAlD
Crizotinib—ABL1—Doxorubicin—Idarubicin—hematologic cancer	2e-05	0.0107	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Idarubicin—hematologic cancer	2e-05	0.0107	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Idarubicin—hematologic cancer	2e-05	0.0107	CbGdCrCtD
Crizotinib—ABCB1—bone marrow—hematologic cancer	1.98e-05	0.000358	CbGeAlD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—hematologic cancer	1.93e-05	0.0103	CbGdCrCtD
Crizotinib—AURKA—Cladribine—Pentostatin—hematologic cancer	1.9e-05	0.0102	CbGdCrCtD
Crizotinib—AURKA—Doxorubicin—Idarubicin—hematologic cancer	1.87e-05	0.00998	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Idarubicin—hematologic cancer	1.87e-05	0.00998	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Idarubicin—hematologic cancer	1.87e-05	0.00998	CbGdCrCtD
Crizotinib—ABCB1—lung—hematologic cancer	1.79e-05	0.000324	CbGeAlD
Crizotinib—AURKA—Cladribine—Clofarabine—hematologic cancer	1.69e-05	0.00907	CbGdCrCtD
Crizotinib—ABCB1—testis—hematologic cancer	1.69e-05	0.000306	CbGeAlD
Crizotinib—CDK7—Idarubicin—Epirubicin—hematologic cancer	1.68e-05	0.00898	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Epirubicin—hematologic cancer	1.68e-05	0.00898	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Epirubicin—hematologic cancer	1.68e-05	0.00898	CbGdCrCtD
Crizotinib—AURKA—Teniposide—Etoposide—hematologic cancer	1.64e-05	0.00879	CbGdCrCtD
Crizotinib—AURKA—Cladribine—Nelarabine—hematologic cancer	1.59e-05	0.00852	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—hematologic cancer	1.55e-05	0.00831	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—hematologic cancer	1.55e-05	0.00831	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—hematologic cancer	1.55e-05	0.00831	CbGdCrCtD
Crizotinib—AURKA—Floxuridine—Cladribine—hematologic cancer	1.51e-05	0.00809	CbGdCrCtD
Crizotinib—AURKA—Clofarabine—Nelarabine—hematologic cancer	1.47e-05	0.00788	CbGdCrCtD
Crizotinib—Gastrointestinal disorder—Etoposide—hematologic cancer	1.46e-05	0.00017	CcSEcCtD
Crizotinib—Body temperature increased—Cisplatin—hematologic cancer	1.46e-05	0.00017	CcSEcCtD
Crizotinib—Asthenia—Mitoxantrone—hematologic cancer	1.46e-05	0.000169	CcSEcCtD
Crizotinib—Asthenia—Irinotecan—hematologic cancer	1.46e-05	0.000169	CcSEcCtD
Crizotinib—Fatigue—Etoposide—hematologic cancer	1.46e-05	0.000169	CcSEcCtD
Crizotinib—Neuropathy peripheral—Epirubicin—hematologic cancer	1.46e-05	0.000169	CcSEcCtD
Crizotinib—Vomiting—Thalidomide—hematologic cancer	1.45e-05	0.000168	CcSEcCtD
Crizotinib—Dizziness—Carmustine—hematologic cancer	1.45e-05	0.000168	CcSEcCtD
Crizotinib—Constipation—Etoposide—hematologic cancer	1.45e-05	0.000168	CcSEcCtD
Crizotinib—Neutropenia—Doxorubicin—hematologic cancer	1.44e-05	0.000168	CcSEcCtD
Crizotinib—Rash—Thalidomide—hematologic cancer	1.44e-05	0.000167	CcSEcCtD
Crizotinib—Dermatitis—Thalidomide—hematologic cancer	1.44e-05	0.000167	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—hematologic cancer	1.44e-05	0.000167	CcSEcCtD
Crizotinib—Dizziness—Alitretinoin—hematologic cancer	1.43e-05	0.000166	CcSEcCtD
Crizotinib—Diarrhoea—Vincristine—hematologic cancer	1.43e-05	0.000166	CcSEcCtD
Crizotinib—Asthenia—Gemcitabine—hematologic cancer	1.42e-05	0.000165	CcSEcCtD
Crizotinib—Dizziness—Ifosfamide—hematologic cancer	1.42e-05	0.000165	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—hematologic cancer	1.41e-05	0.000164	CcSEcCtD
Crizotinib—Hepatobiliary disease—Epirubicin—hematologic cancer	1.41e-05	0.000163	CcSEcCtD
Crizotinib—Vision blurred—Prednisone—hematologic cancer	1.4e-05	0.000163	CcSEcCtD
Crizotinib—Nausea—Thiotepa—hematologic cancer	1.4e-05	0.000162	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—hematologic cancer	1.4e-05	0.000162	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—hematologic cancer	1.4e-05	0.000162	CcSEcCtD
Crizotinib—Oedema—Dexamethasone—hematologic cancer	1.39e-05	0.000162	CcSEcCtD
Crizotinib—Oedema—Betamethasone—hematologic cancer	1.39e-05	0.000162	CcSEcCtD
Crizotinib—Diarrhoea—Mitoxantrone—hematologic cancer	1.39e-05	0.000162	CcSEcCtD
Crizotinib—Diarrhoea—Irinotecan—hematologic cancer	1.39e-05	0.000162	CcSEcCtD
Crizotinib—Vomiting—Carmustine—hematologic cancer	1.39e-05	0.000162	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—hematologic cancer	1.39e-05	0.000161	CcSEcCtD
Crizotinib—Infection—Betamethasone—hematologic cancer	1.38e-05	0.000161	CcSEcCtD
Crizotinib—Infection—Dexamethasone—hematologic cancer	1.38e-05	0.000161	CcSEcCtD
Crizotinib—Dizziness—Vincristine—hematologic cancer	1.38e-05	0.00016	CcSEcCtD
Crizotinib—Rash—Carmustine—hematologic cancer	1.38e-05	0.00016	CcSEcCtD
Crizotinib—Dermatitis—Carmustine—hematologic cancer	1.38e-05	0.00016	CcSEcCtD
Crizotinib—Vomiting—Alitretinoin—hematologic cancer	1.38e-05	0.00016	CcSEcCtD
Crizotinib—Paraesthesia—Triamcinolone—hematologic cancer	1.38e-05	0.00016	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—hematologic cancer	1.38e-05	0.00016	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—hematologic cancer	1.38e-05	0.00016	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—hematologic cancer	1.38e-05	0.00016	CcSEcCtD
Crizotinib—Anaemia—Prednisone—hematologic cancer	1.37e-05	0.000159	CcSEcCtD
Crizotinib—Shock—Betamethasone—hematologic cancer	1.37e-05	0.000159	CcSEcCtD
Crizotinib—Shock—Dexamethasone—hematologic cancer	1.37e-05	0.000159	CcSEcCtD
Crizotinib—Dyspnoea—Triamcinolone—hematologic cancer	1.37e-05	0.000159	CcSEcCtD
Crizotinib—Rash—Alitretinoin—hematologic cancer	1.37e-05	0.000159	CcSEcCtD
Crizotinib—Nervous system disorder—Betamethasone—hematologic cancer	1.37e-05	0.000159	CcSEcCtD
Crizotinib—Nervous system disorder—Dexamethasone—hematologic cancer	1.37e-05	0.000159	CcSEcCtD
Crizotinib—Dermatitis—Alitretinoin—hematologic cancer	1.37e-05	0.000159	CcSEcCtD
Crizotinib—Vomiting—Ifosfamide—hematologic cancer	1.36e-05	0.000158	CcSEcCtD
Crizotinib—Bradycardia—Epirubicin—hematologic cancer	1.36e-05	0.000158	CcSEcCtD
Crizotinib—Diarrhoea—Gemcitabine—hematologic cancer	1.36e-05	0.000157	CcSEcCtD
Crizotinib—Nausea—Thalidomide—hematologic cancer	1.35e-05	0.000157	CcSEcCtD
Crizotinib—Dyspepsia—Triamcinolone—hematologic cancer	1.35e-05	0.000157	CcSEcCtD
Crizotinib—Rash—Ifosfamide—hematologic cancer	1.35e-05	0.000157	CcSEcCtD
Crizotinib—Dermatitis—Ifosfamide—hematologic cancer	1.35e-05	0.000157	CcSEcCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—hematologic cancer	1.35e-05	0.000157	CcSEcCtD
Crizotinib—Dizziness—Irinotecan—hematologic cancer	1.35e-05	0.000156	CcSEcCtD
Crizotinib—Body temperature increased—Etoposide—hematologic cancer	1.34e-05	0.000155	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—hematologic cancer	1.33e-05	0.000155	CcSEcCtD
Crizotinib—Syncope—Prednisone—hematologic cancer	1.33e-05	0.000155	CcSEcCtD
Crizotinib—AURKA—Cytarabine—Clofarabine—hematologic cancer	1.33e-05	0.00713	CbGdCrCtD
Crizotinib—Hypoaesthesia—Epirubicin—hematologic cancer	1.33e-05	0.000154	CcSEcCtD
Crizotinib—Vomiting—Vincristine—hematologic cancer	1.33e-05	0.000154	CcSEcCtD
Crizotinib—Asthenia—Cisplatin—hematologic cancer	1.33e-05	0.000154	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—hematologic cancer	1.33e-05	0.000154	CcSEcCtD
Crizotinib—Fatigue—Triamcinolone—hematologic cancer	1.32e-05	0.000154	CcSEcCtD
Crizotinib—Urinary tract disorder—Epirubicin—hematologic cancer	1.32e-05	0.000153	CcSEcCtD
Crizotinib—Rash—Vincristine—hematologic cancer	1.32e-05	0.000153	CcSEcCtD
Crizotinib—Dermatitis—Vincristine—hematologic cancer	1.32e-05	0.000153	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—hematologic cancer	1.32e-05	0.000153	CcSEcCtD
Crizotinib—Urethral disorder—Epirubicin—hematologic cancer	1.31e-05	0.000152	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisone—hematologic cancer	1.31e-05	0.000152	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—hematologic cancer	1.3e-05	0.000151	CcSEcCtD
Crizotinib—Nausea—Carmustine—hematologic cancer	1.3e-05	0.000151	CcSEcCtD
Crizotinib—Vomiting—Irinotecan—hematologic cancer	1.29e-05	0.00015	CcSEcCtD
Crizotinib—Vomiting—Mitoxantrone—hematologic cancer	1.29e-05	0.00015	CcSEcCtD
Crizotinib—Nausea—Alitretinoin—hematologic cancer	1.29e-05	0.00015	CcSEcCtD
Crizotinib—Visual impairment—Epirubicin—hematologic cancer	1.29e-05	0.000149	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—hematologic cancer	1.29e-05	0.000149	CcSEcCtD
Crizotinib—Rash—Mitoxantrone—hematologic cancer	1.28e-05	0.000149	CcSEcCtD
Crizotinib—Rash—Irinotecan—hematologic cancer	1.28e-05	0.000149	CcSEcCtD
Crizotinib—Dermatitis—Mitoxantrone—hematologic cancer	1.28e-05	0.000149	CcSEcCtD
Crizotinib—Dermatitis—Irinotecan—hematologic cancer	1.28e-05	0.000149	CcSEcCtD
Crizotinib—Nausea—Ifosfamide—hematologic cancer	1.27e-05	0.000148	CcSEcCtD
Crizotinib—Diarrhoea—Cisplatin—hematologic cancer	1.26e-05	0.000147	CcSEcCtD
Crizotinib—Vomiting—Gemcitabine—hematologic cancer	1.26e-05	0.000146	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—hematologic cancer	1.26e-05	0.000146	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	1.26e-05	0.000146	CcSEcCtD
Crizotinib—AURKA—Cytarabine—Nelarabine—hematologic cancer	1.25e-05	0.00671	CbGdCrCtD
Crizotinib—Paraesthesia—Dexamethasone—hematologic cancer	1.25e-05	0.000145	CcSEcCtD
Crizotinib—Paraesthesia—Betamethasone—hematologic cancer	1.25e-05	0.000145	CcSEcCtD
Crizotinib—Rash—Gemcitabine—hematologic cancer	1.25e-05	0.000145	CcSEcCtD
Crizotinib—Dermatitis—Gemcitabine—hematologic cancer	1.25e-05	0.000145	CcSEcCtD
Crizotinib—Eye disorder—Epirubicin—hematologic cancer	1.25e-05	0.000145	CcSEcCtD
Crizotinib—AURKA—Cladribine—Fludarabine—hematologic cancer	1.24e-05	0.00665	CbGdCrCtD
Crizotinib—Malnutrition—Methotrexate—hematologic cancer	1.24e-05	0.000144	CcSEcCtD
Crizotinib—Nausea—Vincristine—hematologic cancer	1.24e-05	0.000144	CcSEcCtD
Crizotinib—Cardiac disorder—Epirubicin—hematologic cancer	1.24e-05	0.000144	CcSEcCtD
Crizotinib—Hypoaesthesia—Doxorubicin—hematologic cancer	1.23e-05	0.000143	CcSEcCtD
Crizotinib—Dyspepsia—Betamethasone—hematologic cancer	1.23e-05	0.000142	CcSEcCtD
Crizotinib—Dyspepsia—Dexamethasone—hematologic cancer	1.23e-05	0.000142	CcSEcCtD
Crizotinib—ABCB1—lymph node—hematologic cancer	1.22e-05	0.000222	CbGeAlD
Crizotinib—Urinary tract disorder—Doxorubicin—hematologic cancer	1.22e-05	0.000142	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—hematologic cancer	1.22e-05	0.000141	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—hematologic cancer	1.22e-05	0.000141	CcSEcCtD
Crizotinib—Asthenia—Etoposide—hematologic cancer	1.22e-05	0.000141	CcSEcCtD
Crizotinib—Body temperature increased—Triamcinolone—hematologic cancer	1.21e-05	0.000141	CcSEcCtD
Crizotinib—Oedema—Prednisone—hematologic cancer	1.21e-05	0.000141	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—hematologic cancer	1.21e-05	0.000141	CcSEcCtD
Crizotinib—Decreased appetite—Betamethasone—hematologic cancer	1.21e-05	0.000141	CcSEcCtD
Crizotinib—Decreased appetite—Dexamethasone—hematologic cancer	1.21e-05	0.000141	CcSEcCtD
Crizotinib—Nausea—Irinotecan—hematologic cancer	1.21e-05	0.00014	CcSEcCtD
Crizotinib—Nausea—Mitoxantrone—hematologic cancer	1.21e-05	0.00014	CcSEcCtD
Crizotinib—Infection—Prednisone—hematologic cancer	1.21e-05	0.00014	CcSEcCtD
Crizotinib—Mediastinal disorder—Epirubicin—hematologic cancer	1.2e-05	0.00014	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.2e-05	0.00014	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.2e-05	0.00014	CcSEcCtD
Crizotinib—Fatigue—Betamethasone—hematologic cancer	1.2e-05	0.000139	CcSEcCtD
Crizotinib—Fatigue—Dexamethasone—hematologic cancer	1.2e-05	0.000139	CcSEcCtD
Crizotinib—Shock—Prednisone—hematologic cancer	1.19e-05	0.000139	CcSEcCtD
Crizotinib—Arrhythmia—Epirubicin—hematologic cancer	1.19e-05	0.000138	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—hematologic cancer	1.19e-05	0.000138	CcSEcCtD
Crizotinib—Nervous system disorder—Prednisone—hematologic cancer	1.19e-05	0.000138	CcSEcCtD
Crizotinib—Skin disorder—Prednisone—hematologic cancer	1.18e-05	0.000137	CcSEcCtD
Crizotinib—Nausea—Gemcitabine—hematologic cancer	1.18e-05	0.000137	CcSEcCtD
Crizotinib—Vomiting—Cisplatin—hematologic cancer	1.18e-05	0.000136	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—hematologic cancer	1.17e-05	0.000136	CcSEcCtD
Crizotinib—Rash—Cisplatin—hematologic cancer	1.17e-05	0.000135	CcSEcCtD
Crizotinib—Dermatitis—Cisplatin—hematologic cancer	1.16e-05	0.000135	CcSEcCtD
Crizotinib—Malnutrition—Epirubicin—hematologic cancer	1.16e-05	0.000135	CcSEcCtD
Crizotinib—Diarrhoea—Etoposide—hematologic cancer	1.16e-05	0.000134	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—hematologic cancer	1.16e-05	0.000134	CcSEcCtD
Crizotinib—AURKA—Clofarabine—Fludarabine—hematologic cancer	1.15e-05	0.00615	CbGdCrCtD
Crizotinib—Anaemia—Methotrexate—hematologic cancer	1.15e-05	0.000133	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—hematologic cancer	1.15e-05	0.000133	CcSEcCtD
Crizotinib—Dysgeusia—Epirubicin—hematologic cancer	1.14e-05	0.000132	CcSEcCtD
Crizotinib—Dizziness—Etoposide—hematologic cancer	1.12e-05	0.00013	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—hematologic cancer	1.11e-05	0.000129	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—hematologic cancer	1.11e-05	0.000129	CcSEcCtD
Crizotinib—Dizziness—Prednisolone—hematologic cancer	1.1e-05	0.000128	CcSEcCtD
Crizotinib—Arrhythmia—Doxorubicin—hematologic cancer	1.1e-05	0.000128	CcSEcCtD
Crizotinib—Asthenia—Triamcinolone—hematologic cancer	1.1e-05	0.000128	CcSEcCtD
Crizotinib—Body temperature increased—Dexamethasone—hematologic cancer	1.1e-05	0.000128	CcSEcCtD
Crizotinib—Body temperature increased—Betamethasone—hematologic cancer	1.1e-05	0.000128	CcSEcCtD
Crizotinib—Nausea—Cisplatin—hematologic cancer	1.1e-05	0.000127	CcSEcCtD
Crizotinib—Vision blurred—Epirubicin—hematologic cancer	1.1e-05	0.000127	CcSEcCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—hematologic cancer	1.09e-05	0.00585	CbGdCrCtD
Crizotinib—PLK4—Idarubicin—Epirubicin—hematologic cancer	1.09e-05	0.00585	CbGdCrCtD
Crizotinib—Paraesthesia—Prednisone—hematologic cancer	1.09e-05	0.000126	CcSEcCtD
Crizotinib—AURKA—Clofarabine—Cytarabine—hematologic cancer	1.09e-05	0.00581	CbGdCrCtD
Crizotinib—Vomiting—Etoposide—hematologic cancer	1.08e-05	0.000125	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—hematologic cancer	1.08e-05	0.000125	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—hematologic cancer	1.08e-05	0.000125	CcSEcCtD
Crizotinib—Dyspepsia—Prednisone—hematologic cancer	1.07e-05	0.000124	CcSEcCtD
Crizotinib—Rash—Etoposide—hematologic cancer	1.07e-05	0.000124	CcSEcCtD
Crizotinib—Dermatitis—Etoposide—hematologic cancer	1.07e-05	0.000124	CcSEcCtD
Crizotinib—AURKA—Clofarabine—Cladribine—hematologic cancer	1.06e-05	0.00566	CbGdCrCtD
Crizotinib—Decreased appetite—Prednisone—hematologic cancer	1.06e-05	0.000122	CcSEcCtD
Crizotinib—Dysgeusia—Doxorubicin—hematologic cancer	1.05e-05	0.000122	CcSEcCtD
Crizotinib—Rash—Prednisolone—hematologic cancer	1.05e-05	0.000122	CcSEcCtD
Crizotinib—Dermatitis—Prednisolone—hematologic cancer	1.05e-05	0.000122	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.05e-05	0.000122	CcSEcCtD
Crizotinib—Fatigue—Prednisone—hematologic cancer	1.05e-05	0.000121	CcSEcCtD
Crizotinib—Syncope—Epirubicin—hematologic cancer	1.04e-05	0.000121	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—hematologic cancer	1.04e-05	0.000121	CcSEcCtD
Crizotinib—Constipation—Prednisone—hematologic cancer	1.04e-05	0.00012	CcSEcCtD
Crizotinib—Loss of consciousness—Epirubicin—hematologic cancer	1.02e-05	0.000119	CcSEcCtD
Crizotinib—Dizziness—Triamcinolone—hematologic cancer	1.02e-05	0.000118	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—hematologic cancer	1.01e-05	0.000118	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—hematologic cancer	1.01e-05	0.00542	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—hematologic cancer	1.01e-05	0.00542	CbGdCrCtD
Crizotinib—Infection—Methotrexate—hematologic cancer	1.01e-05	0.000117	CcSEcCtD
Crizotinib—Nausea—Etoposide—hematologic cancer	1.01e-05	0.000117	CcSEcCtD
Crizotinib—AURKA—Gemcitabine—Cytarabine—hematologic cancer	1.01e-05	0.00538	CbGdCrCtD
Crizotinib—Asthenia—Betamethasone—hematologic cancer	1e-05	0.000116	CcSEcCtD
Crizotinib—Asthenia—Dexamethasone—hematologic cancer	1e-05	0.000116	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—hematologic cancer	9.95e-06	0.000115	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—hematologic cancer	9.95e-06	0.000115	CcSEcCtD
Crizotinib—Nausea—Prednisolone—hematologic cancer	9.92e-06	0.000115	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—hematologic cancer	9.85e-06	0.000114	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	9.84e-06	0.000114	CcSEcCtD
Crizotinib—AURKA—Cytarabine—Fludarabine—hematologic cancer	9.78e-06	0.00523	CbGdCrCtD
Crizotinib—Vomiting—Triamcinolone—hematologic cancer	9.77e-06	0.000113	CcSEcCtD
Crizotinib—Rash—Triamcinolone—hematologic cancer	9.69e-06	0.000112	CcSEcCtD
Crizotinib—Dermatitis—Triamcinolone—hematologic cancer	9.68e-06	0.000112	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—hematologic cancer	9.65e-06	0.000112	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—hematologic cancer	9.63e-06	0.000112	CcSEcCtD
Crizotinib—Body temperature increased—Prednisone—hematologic cancer	9.6e-06	0.000111	CcSEcCtD
Crizotinib—Diarrhoea—Dexamethasone—hematologic cancer	9.54e-06	0.000111	CcSEcCtD
Crizotinib—Diarrhoea—Betamethasone—hematologic cancer	9.54e-06	0.000111	CcSEcCtD
Crizotinib—Oedema—Epirubicin—hematologic cancer	9.49e-06	0.00011	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—hematologic cancer	9.46e-06	0.00011	CcSEcCtD
Crizotinib—Infection—Epirubicin—hematologic cancer	9.43e-06	0.000109	CcSEcCtD
Crizotinib—Shock—Epirubicin—hematologic cancer	9.34e-06	0.000108	CcSEcCtD
Crizotinib—Nervous system disorder—Epirubicin—hematologic cancer	9.31e-06	0.000108	CcSEcCtD
Crizotinib—AURKA—Cytarabine—Gemcitabine—hematologic cancer	9.24e-06	0.00494	CbGdCrCtD
Crizotinib—Skin disorder—Epirubicin—hematologic cancer	9.22e-06	0.000107	CcSEcCtD
Crizotinib—Dizziness—Dexamethasone—hematologic cancer	9.22e-06	0.000107	CcSEcCtD
Crizotinib—Dizziness—Betamethasone—hematologic cancer	9.22e-06	0.000107	CcSEcCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—hematologic cancer	9.2e-06	0.00492	CbGdCrCtD
Crizotinib—ABL1—Doxorubicin—Epirubicin—hematologic cancer	9.2e-06	0.00492	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Epirubicin—hematologic cancer	9.2e-06	0.00492	CbGdCrCtD
Crizotinib—Nausea—Triamcinolone—hematologic cancer	9.12e-06	0.000106	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—hematologic cancer	9.11e-06	0.000106	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	9.1e-06	0.000106	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—hematologic cancer	9.04e-06	0.000105	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—hematologic cancer	8.93e-06	0.000104	CcSEcCtD
Crizotinib—Vomiting—Betamethasone—hematologic cancer	8.86e-06	0.000103	CcSEcCtD
Crizotinib—Vomiting—Dexamethasone—hematologic cancer	8.86e-06	0.000103	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—hematologic cancer	8.82e-06	0.000102	CcSEcCtD
Crizotinib—Rash—Betamethasone—hematologic cancer	8.79e-06	0.000102	CcSEcCtD
Crizotinib—Rash—Dexamethasone—hematologic cancer	8.79e-06	0.000102	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—hematologic cancer	8.78e-06	0.000102	CcSEcCtD
Crizotinib—Dermatitis—Betamethasone—hematologic cancer	8.78e-06	0.000102	CcSEcCtD
Crizotinib—Dermatitis—Dexamethasone—hematologic cancer	8.78e-06	0.000102	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—hematologic cancer	8.76e-06	0.000102	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—hematologic cancer	8.75e-06	0.000101	CcSEcCtD
Crizotinib—Infection—Doxorubicin—hematologic cancer	8.73e-06	0.000101	CcSEcCtD
Crizotinib—Asthenia—Prednisone—hematologic cancer	8.71e-06	0.000101	CcSEcCtD
Crizotinib—Shock—Doxorubicin—hematologic cancer	8.64e-06	0.0001	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—hematologic cancer	8.61e-06	9.99e-05	CcSEcCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—hematologic cancer	8.56e-06	0.00458	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—hematologic cancer	8.56e-06	0.00458	CbGdCrCtD
Crizotinib—AURKA—Doxorubicin—Epirubicin—hematologic cancer	8.56e-06	0.00458	CbGdCrCtD
Crizotinib—Skin disorder—Doxorubicin—hematologic cancer	8.53e-06	9.9e-05	CcSEcCtD
Crizotinib—Paraesthesia—Epirubicin—hematologic cancer	8.52e-06	9.89e-05	CcSEcCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—hematologic cancer	8.51e-06	0.00455	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—hematologic cancer	8.51e-06	0.00455	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—hematologic cancer	8.51e-06	0.00455	CbGdCrCtD
Crizotinib—Dyspnoea—Epirubicin—hematologic cancer	8.46e-06	9.82e-05	CcSEcCtD
Crizotinib—Dyspepsia—Epirubicin—hematologic cancer	8.36e-06	9.7e-05	CcSEcCtD
Crizotinib—Diarrhoea—Prednisone—hematologic cancer	8.31e-06	9.64e-05	CcSEcCtD
Crizotinib—Nausea—Dexamethasone—hematologic cancer	8.28e-06	9.61e-05	CcSEcCtD
Crizotinib—Nausea—Betamethasone—hematologic cancer	8.28e-06	9.61e-05	CcSEcCtD
Crizotinib—Decreased appetite—Epirubicin—hematologic cancer	8.25e-06	9.58e-05	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—hematologic cancer	8.2e-06	9.51e-05	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—hematologic cancer	8.19e-06	9.5e-05	CcSEcCtD
Crizotinib—Constipation—Epirubicin—hematologic cancer	8.12e-06	9.42e-05	CcSEcCtD
Crizotinib—Dizziness—Prednisone—hematologic cancer	8.03e-06	9.31e-05	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—hematologic cancer	8.02e-06	9.3e-05	CcSEcCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—hematologic cancer	7.92e-06	0.00424	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—hematologic cancer	7.92e-06	0.00424	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—hematologic cancer	7.92e-06	0.00424	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Dexamethasone—hematologic cancer	7.9e-06	0.00423	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Betamethasone—hematologic cancer	7.9e-06	0.00423	CbGdCrCtD
Crizotinib—Paraesthesia—Doxorubicin—hematologic cancer	7.89e-06	9.15e-05	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—hematologic cancer	7.83e-06	9.09e-05	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—hematologic cancer	7.73e-06	8.97e-05	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Triamcinolone—hematologic cancer	7.72e-06	0.00413	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Triamcinolone—hematologic cancer	7.72e-06	0.00413	CbGdCrCtD
Crizotinib—Vomiting—Prednisone—hematologic cancer	7.72e-06	8.95e-05	CcSEcCtD
Crizotinib—Rash—Prednisone—hematologic cancer	7.65e-06	8.88e-05	CcSEcCtD
Crizotinib—Dermatitis—Prednisone—hematologic cancer	7.65e-06	8.87e-05	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—hematologic cancer	7.64e-06	8.86e-05	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	7.58e-06	8.8e-05	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—hematologic cancer	7.57e-06	8.79e-05	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—hematologic cancer	7.51e-06	8.72e-05	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—hematologic cancer	7.5e-06	8.71e-05	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Prednisone—hematologic cancer	7.33e-06	0.00392	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Prednisone—hematologic cancer	7.33e-06	0.00392	CbGdCrCtD
Crizotinib—Asthenia—Methotrexate—hematologic cancer	7.28e-06	8.44e-05	CcSEcCtD
Crizotinib—Nausea—Prednisone—hematologic cancer	7.21e-06	8.37e-05	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Prednisolone—hematologic cancer	7.15e-06	0.00383	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Prednisolone—hematologic cancer	7.15e-06	0.00383	CbGdCrCtD
Crizotinib—Body temperature increased—Doxorubicin—hematologic cancer	6.94e-06	8.06e-05	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—hematologic cancer	6.94e-06	8.05e-05	CcSEcCtD
Crizotinib—Asthenia—Epirubicin—hematologic cancer	6.81e-06	7.9e-05	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—hematologic cancer	6.71e-06	7.78e-05	CcSEcCtD
Crizotinib—Diarrhoea—Epirubicin—hematologic cancer	6.5e-06	7.54e-05	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—hematologic cancer	6.45e-06	7.48e-05	CcSEcCtD
Crizotinib—Rash—Methotrexate—hematologic cancer	6.4e-06	7.42e-05	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—hematologic cancer	6.39e-06	7.41e-05	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—hematologic cancer	6.3e-06	7.31e-05	CcSEcCtD
Crizotinib—Dizziness—Epirubicin—hematologic cancer	6.28e-06	7.28e-05	CcSEcCtD
Crizotinib—Vomiting—Epirubicin—hematologic cancer	6.04e-06	7e-05	CcSEcCtD
Crizotinib—Nausea—Methotrexate—hematologic cancer	6.03e-06	6.99e-05	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—hematologic cancer	6.01e-06	6.97e-05	CcSEcCtD
Crizotinib—Rash—Epirubicin—hematologic cancer	5.99e-06	6.94e-05	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—hematologic cancer	5.98e-06	6.94e-05	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—hematologic cancer	5.81e-06	6.74e-05	CcSEcCtD
Crizotinib—Nausea—Epirubicin—hematologic cancer	5.64e-06	6.54e-05	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—hematologic cancer	5.59e-06	6.48e-05	CcSEcCtD
Crizotinib—Rash—Doxorubicin—hematologic cancer	5.54e-06	6.43e-05	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—hematologic cancer	5.53e-06	6.42e-05	CcSEcCtD
Crizotinib—Nausea—Doxorubicin—hematologic cancer	5.22e-06	6.05e-05	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Betamethasone—hematologic cancer	5.09e-06	0.00272	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Dexamethasone—hematologic cancer	5.09e-06	0.00272	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Triamcinolone—hematologic cancer	4.97e-06	0.00266	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Triamcinolone—hematologic cancer	4.97e-06	0.00266	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisone—hematologic cancer	4.72e-06	0.00253	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisone—hematologic cancer	4.72e-06	0.00253	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisolone—hematologic cancer	4.61e-06	0.00247	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisolone—hematologic cancer	4.61e-06	0.00247	CbGdCrCtD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—hematologic cancer	1.19e-07	1.14e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTPN11—hematologic cancer	1.18e-07	1.13e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EP300—hematologic cancer	1.18e-07	1.12e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—hematologic cancer	1.17e-07	1.12e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—hematologic cancer	1.17e-07	1.12e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—hematologic cancer	1.17e-07	1.12e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—hematologic cancer	1.17e-07	1.12e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—hematologic cancer	1.17e-07	1.12e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTR—hematologic cancer	1.17e-07	1.12e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.17e-07	1.12e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—hematologic cancer	1.16e-07	1.11e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK3—hematologic cancer	1.16e-07	1.11e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—hematologic cancer	1.16e-07	1.11e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—hematologic cancer	1.15e-07	1.1e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—hematologic cancer	1.15e-07	1.1e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTM1—hematologic cancer	1.15e-07	1.1e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NCOR1—hematologic cancer	1.15e-07	1.1e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—hematologic cancer	1.15e-07	1.1e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CREB1—hematologic cancer	1.15e-07	1.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGF2—hematologic cancer	1.14e-07	1.09e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO2—hematologic cancer	1.14e-07	1.09e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1A—hematologic cancer	1.14e-07	1.09e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—hematologic cancer	1.14e-07	1.09e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—hematologic cancer	1.14e-07	1.09e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—hematologic cancer	1.14e-07	1.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—hematologic cancer	1.14e-07	1.09e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—JUN—hematologic cancer	1.14e-07	1.09e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BRAF—hematologic cancer	1.13e-07	1.08e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—hematologic cancer	1.13e-07	1.08e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3R1—hematologic cancer	1.13e-07	1.08e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CG—hematologic cancer	1.13e-07	1.08e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—hematologic cancer	1.13e-07	1.08e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—hematologic cancer	1.13e-07	1.08e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—hematologic cancer	1.12e-07	1.07e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—hematologic cancer	1.12e-07	1.07e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—hematologic cancer	1.12e-07	1.07e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—hematologic cancer	1.12e-07	1.07e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6R—hematologic cancer	1.12e-07	1.07e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—hematologic cancer	1.12e-07	1.07e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—hematologic cancer	1.12e-07	1.07e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CREBBP—hematologic cancer	1.12e-07	1.07e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.11e-07	1.06e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—hematologic cancer	1.11e-07	1.06e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—hematologic cancer	1.1e-07	1.06e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—hematologic cancer	1.1e-07	1.06e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—hematologic cancer	1.1e-07	1.05e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—hematologic cancer	1.1e-07	1.05e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—hematologic cancer	1.1e-07	1.05e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK3—hematologic cancer	1.1e-07	1.05e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—hematologic cancer	1.1e-07	1.05e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JAK2—hematologic cancer	1.1e-07	1.05e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—hematologic cancer	1.1e-07	1.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—hematologic cancer	1.09e-07	1.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—hematologic cancer	1.09e-07	1.04e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—hematologic cancer	1.09e-07	1.04e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—hematologic cancer	1.09e-07	1.04e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—hematologic cancer	1.09e-07	1.04e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SDC1—hematologic cancer	1.08e-07	1.04e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—hematologic cancer	1.08e-07	1.03e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK8—hematologic cancer	1.07e-07	1.03e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—hematologic cancer	1.07e-07	1.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MDM2—hematologic cancer	1.07e-07	1.02e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—hematologic cancer	1.07e-07	1.02e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—hematologic cancer	1.07e-07	1.02e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—hematologic cancer	1.07e-07	1.02e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAP2K1—hematologic cancer	1.07e-07	1.02e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—hematologic cancer	1.07e-07	1.02e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—JUN—hematologic cancer	1.06e-07	1.02e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—hematologic cancer	1.06e-07	1.01e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CD—hematologic cancer	1.06e-07	1.01e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—hematologic cancer	1.06e-07	1.01e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—hematologic cancer	1.05e-07	1.01e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK3—hematologic cancer	1.05e-07	1.01e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—hematologic cancer	1.05e-07	1e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CREBBP—hematologic cancer	1.05e-07	1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MTOR—hematologic cancer	1.04e-07	9.96e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CB—hematologic cancer	1.04e-07	9.96e-07	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—hematologic cancer	1.04e-07	9.96e-07	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—hematologic cancer	1.04e-07	9.94e-07	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—hematologic cancer	1.04e-07	9.92e-07	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—hematologic cancer	1.04e-07	9.9e-07	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—hematologic cancer	1.03e-07	9.89e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—hematologic cancer	1.03e-07	9.85e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—hematologic cancer	1.03e-07	9.83e-07	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—hematologic cancer	1.02e-07	9.75e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SRC—hematologic cancer	1.02e-07	9.74e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—hematologic cancer	1.02e-07	9.73e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—hematologic cancer	1.02e-07	9.71e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—hematologic cancer	1.01e-07	9.69e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGF2—hematologic cancer	1.01e-07	9.69e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK8—hematologic cancer	1.01e-07	9.61e-07	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—hematologic cancer	1.01e-07	9.61e-07	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—hematologic cancer	1e-07	9.59e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—hematologic cancer	1e-07	9.59e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3R1—hematologic cancer	1e-07	9.55e-07	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—hematologic cancer	9.93e-08	9.5e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CD—hematologic cancer	9.93e-08	9.49e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—hematologic cancer	9.92e-08	9.48e-07	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—hematologic cancer	9.87e-08	9.44e-07	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—hematologic cancer	9.86e-08	9.42e-07	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—hematologic cancer	9.83e-08	9.39e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—hematologic cancer	9.83e-08	9.39e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—hematologic cancer	9.81e-08	9.37e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—hematologic cancer	9.8e-08	9.37e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—hematologic cancer	9.8e-08	9.36e-07	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—hematologic cancer	9.79e-08	9.36e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—hematologic cancer	9.78e-08	9.35e-07	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—hematologic cancer	9.75e-08	9.32e-07	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—hematologic cancer	9.75e-08	9.32e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK3—hematologic cancer	9.73e-08	9.3e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JAK2—hematologic cancer	9.71e-08	9.28e-07	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—hematologic cancer	9.62e-08	9.19e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—hematologic cancer	9.59e-08	9.16e-07	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—hematologic cancer	9.58e-08	9.16e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—hematologic cancer	9.57e-08	9.15e-07	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—hematologic cancer	9.57e-08	9.15e-07	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—hematologic cancer	9.54e-08	9.12e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SRC—hematologic cancer	9.54e-08	9.11e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MDM2—hematologic cancer	9.48e-08	9.06e-07	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—hematologic cancer	9.47e-08	9.05e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—hematologic cancer	9.46e-08	9.04e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—hematologic cancer	9.44e-08	9.02e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK3—hematologic cancer	9.39e-08	8.97e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3R1—hematologic cancer	9.37e-08	8.96e-07	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—hematologic cancer	9.33e-08	8.92e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—hematologic cancer	9.33e-08	8.92e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JUN—hematologic cancer	9.31e-08	8.9e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—hematologic cancer	9.29e-08	8.88e-07	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—hematologic cancer	9.26e-08	8.85e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CB—hematologic cancer	9.23e-08	8.82e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MTOR—hematologic cancer	9.23e-08	8.82e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NQO1—hematologic cancer	9.22e-08	8.81e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CD44—hematologic cancer	9.22e-08	8.81e-07	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—hematologic cancer	9.2e-08	8.8e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—hematologic cancer	9.2e-08	8.79e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—hematologic cancer	9.17e-08	8.77e-07	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—hematologic cancer	9.17e-08	8.77e-07	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—hematologic cancer	9.17e-08	8.76e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—hematologic cancer	9.13e-08	8.73e-07	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—hematologic cancer	9.12e-08	8.72e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—hematologic cancer	9.11e-08	8.71e-07	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—hematologic cancer	9.09e-08	8.69e-07	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—hematologic cancer	9.07e-08	8.67e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—hematologic cancer	9.03e-08	8.63e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—hematologic cancer	9.01e-08	8.61e-07	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—hematologic cancer	8.86e-08	8.46e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK8—hematologic cancer	8.81e-08	8.42e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK3—hematologic cancer	8.79e-08	8.4e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—hematologic cancer	8.74e-08	8.36e-07	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—hematologic cancer	8.73e-08	8.34e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYCS—hematologic cancer	8.73e-08	8.34e-07	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—hematologic cancer	8.7e-08	8.32e-07	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—hematologic cancer	8.7e-08	8.31e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	8.67e-08	8.29e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—hematologic cancer	8.66e-08	8.28e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CB—hematologic cancer	8.65e-08	8.27e-07	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—hematologic cancer	8.61e-08	8.23e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—hematologic cancer	8.59e-08	8.21e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—hematologic cancer	8.54e-08	8.17e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—hematologic cancer	8.52e-08	8.15e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CG—hematologic cancer	8.52e-08	8.14e-07	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—hematologic cancer	8.49e-08	8.12e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—hematologic cancer	8.49e-08	8.11e-07	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—hematologic cancer	8.48e-08	8.1e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—hematologic cancer	8.47e-08	8.1e-07	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—hematologic cancer	8.46e-08	8.09e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—hematologic cancer	8.44e-08	8.06e-07	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—hematologic cancer	8.39e-08	8.02e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SRC—hematologic cancer	8.35e-08	7.98e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—hematologic cancer	8.26e-08	7.89e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JUN—hematologic cancer	8.24e-08	7.88e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—hematologic cancer	8.13e-08	7.77e-07	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—hematologic cancer	8.05e-08	7.7e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—hematologic cancer	8.05e-08	7.7e-07	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—hematologic cancer	8.05e-08	7.69e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—hematologic cancer	8.03e-08	7.68e-07	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—hematologic cancer	8.03e-08	7.68e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—hematologic cancer	8.03e-08	7.68e-07	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—hematologic cancer	8.03e-08	7.67e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—hematologic cancer	7.99e-08	7.64e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—hematologic cancer	7.97e-08	7.62e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CREBBP—hematologic cancer	7.9e-08	7.55e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—hematologic cancer	7.9e-08	7.55e-07	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—hematologic cancer	7.82e-08	7.47e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK8—hematologic cancer	7.8e-08	7.45e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—hematologic cancer	7.75e-08	7.41e-07	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—hematologic cancer	7.7e-08	7.36e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK3—hematologic cancer	7.69e-08	7.35e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—hematologic cancer	7.69e-08	7.35e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—hematologic cancer	7.6e-08	7.27e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—hematologic cancer	7.5e-08	7.17e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CD—hematologic cancer	7.49e-08	7.16e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—hematologic cancer	7.48e-08	7.15e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—hematologic cancer	7.48e-08	7.14e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—hematologic cancer	7.47e-08	7.14e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—hematologic cancer	7.43e-08	7.1e-07	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—hematologic cancer	7.41e-08	7.08e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—hematologic cancer	7.39e-08	7.07e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—hematologic cancer	7.28e-08	6.96e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—hematologic cancer	7.25e-08	6.93e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—hematologic cancer	7.2e-08	6.88e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—hematologic cancer	7.17e-08	6.85e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—hematologic cancer	7.13e-08	6.81e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—hematologic cancer	7.13e-08	6.81e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—hematologic cancer	7.11e-08	6.8e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—hematologic cancer	7.11e-08	6.8e-07	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—hematologic cancer	7.11e-08	6.79e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3R1—hematologic cancer	7.07e-08	6.76e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—hematologic cancer	7.07e-08	6.76e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NCOR1—hematologic cancer	7.07e-08	6.76e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—hematologic cancer	7.02e-08	6.71e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—hematologic cancer	6.92e-08	6.61e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—hematologic cancer	6.86e-08	6.56e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK3—hematologic cancer	6.81e-08	6.51e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—hematologic cancer	6.71e-08	6.41e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—hematologic cancer	6.63e-08	6.33e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—hematologic cancer	6.61e-08	6.32e-07	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—hematologic cancer	6.56e-08	6.27e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CB—hematologic cancer	6.53e-08	6.24e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—hematologic cancer	6.42e-08	6.14e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—hematologic cancer	6.35e-08	6.07e-07	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—hematologic cancer	6.33e-08	6.05e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—hematologic cancer	6.25e-08	5.97e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—hematologic cancer	6.15e-08	5.87e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—hematologic cancer	6.12e-08	5.85e-07	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—hematologic cancer	5.93e-08	5.66e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—hematologic cancer	5.88e-08	5.62e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—hematologic cancer	5.64e-08	5.39e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—hematologic cancer	5.63e-08	5.38e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—hematologic cancer	5.62e-08	5.38e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—hematologic cancer	5.44e-08	5.2e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—hematologic cancer	5.38e-08	5.14e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—hematologic cancer	5.27e-08	5.04e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	5.25e-08	5.02e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—hematologic cancer	5.2e-08	4.97e-07	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—hematologic cancer	5.19e-08	4.96e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—hematologic cancer	4.98e-08	4.76e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CREBBP—hematologic cancer	4.87e-08	4.65e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	4.61e-08	4.41e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—hematologic cancer	4.59e-08	4.39e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—hematologic cancer	4.56e-08	4.35e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	4.36e-08	4.16e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—hematologic cancer	4.31e-08	4.12e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	4.02e-08	3.84e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—hematologic cancer	3.98e-08	3.8e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—hematologic cancer	3.48e-08	3.32e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—hematologic cancer	3.31e-08	3.17e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—hematologic cancer	3.25e-08	3.11e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.45e-08	2.34e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—hematologic cancer	2e-08	1.91e-07	CbGpPWpGaD
